CD274 and renal cell adenocarcinoma: In a phase 1 trial in treatment-refractory renal cell cancer (RCC), ciforadenant (Corvus Pharmaceuticals) achieved an ORR of 3% as monotherapy and 11% in combination with atezolizumab, a PD-L1 inhibitor (185).